332903-83-0

Basic information

• Product Name: 1-(2-Chloro-6-fluorophenyl)-5-methylindolin-2-one
• Synonyms: 1-(2-Chloro-6-fluorophenyl)-5-methylindolin-2-one
• CAS NO: 332903-83-0
• Molecular Formula: C₁₅H₁₁ClFNO
• Molecular Weight: 275.7053432
• Mol File: 332903-83-0.mol

Chemical Properties

• Melting Point: 137-138 °C(Solv: isopropanol (67-63-0))
• Boiling Point: 478.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.360±0.06 g/cm3(Predicted)
• PKA: -3.88±0.20(Predicted)
• CAS DataBase Reference: 1-(2-Chloro-6-fluorophenyl)-5-methylindolin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-Chloro-6-fluorophenyl)-5-methylindolin-2-one(332903-83-0)
• EPA Substance Registry System: 1-(2-Chloro-6-fluorophenyl)-5-methylindolin-2-one(332903-83-0)

Safety Data

• Hazardous Substances Data: 332903-83-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-Chloro-6-fluorophenyl)-5-methylindolin-2-one is used as a potential therapeutic agent for its anticancer properties. Research indicates that CFIMI may have effects against various types of cancer, making it a candidate for further study and development in cancer treatment.
Additionally, due to its anti-inflammatory and antiviral effects, 1-(2-Chloro-6-fluorophenyl)-5-methylindolin-2-one may also be used as a potential agent in the treatment of inflammatory diseases and viral infections. However, further research is necessary to fully understand its pharmacological properties and potential applications in these areas.

Upstream product

• 332903-74-9 N-(2-chloro-6-fluoro-phenyl)-4-methylaniline 
• 220991-20-8 lumiracoxib 
• 7440-44-0 pyrographite 
• 332903-78-3 2-chloro-N-(2-chloro-6-fluoro-phenyl)-N-p-tolylacetamide 
• 79-04-9 chloroacetyl chloride 
• 817621-52-6 4-(2-chloro-6-fluoro-phenylamino)benzoic acid ethyl ester 
• 309721-44-6 2-bromo-3-fluoro-chlorobenzene 
• 16634-82-5 N-(p-tolyl)-2-chloroacetamide 
• 106-49-0 p-toluidine 
• 363-51-9 2-chloro-6-fluoroaniline 
• 817621-77-5 1-(2-chloro-6-fluoro-phenyl)-5-methyl-1,4,5,6-tetrahydro-indol-2-one 

Downstream Products

• 220991-20-8 lumiracoxib 

Relevant articles and documents

Synthesis, characterization and pharmacological evaluation of1-(2-chloro-6-fluorophenyl)-5-methylindolin-2-one: A new anti-inflammatory compound with reduced gastric ulceration properties

The new compound 1-(2-chloro-6-fluorophenyl)-5-methylindolin-2-one (1), designed using the prodrug approach, was easily obtained in 85% yield and characterized by nuclear magnetic resonance, elemental analysis, mass spectrometry and infrared spectroscopy.

Process for phenylacetic acid derivatives

A process for the production of a compound of Formula I, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable prodrug ester thereof, comprising cleaving a lactam of formula II wherein the symbols are as defined, with a base; and precursors therefor and processes for the preparation of the precursors. The compounds of Formula I are pharmaceutically active compounds which are selective inhibitors of Cyclooxygenase II.

Synthesis of new N-aryl oxindoles as intermediates for pharmacologically active compounds

Various new N-aryl oxindoles were synthesized as intermediates for the preparation of pharmacologically active 2-(N-arylamino)-phenylacetic acids. Two novel approaches were explored for the construction of diarylamine and N-aryl oxindole core structures, in addition to Buchwald-arylamination and Smiles rearrangement. Condensation of anilines with 2-oxo-cyclohexylidene-acetic acid derivatives and subsequent dehydrogenation is a new and viable method for the preparation of N-aryl oxindoles. Graphical Abstract.

Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives

Disclosed are the compounds of formula I wherein R is methyl or ethyl; R1is chloro or fluoro; R2is hydrogen or fluoro; R3is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy; R4is hydrogen or fluoro; and R5is chloro, fluoro, trifluoromethyl or methyl; and pharmaceutically acceptable salts thereof, as selective COX-2 cyclooxygenase inhibitors; and pharmaceutically acceptable prodrug esters thereof.